开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2024-06-22 侠胆医心来自威斯康星

审稿速度:3.0 | 投稿命中率:95.0
经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。

85 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-03-21 woshiliwj 来自浙江省

这个杂志被踢出sci了！

137 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-03-21 ms6000002114457146

小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么

141 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-03-26 ms2000002146747069 来自四川省

这个杂志在wos还能检索到吗

138 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-03-22 Drwurh 来自广东省

偏重的研究方向：神经科学;免疫
经验分享：已被踢sci了，感觉撤稿重投了

141 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-11-23 ms4000001680289394

偏重的研究方向：生物信息学;药效学及机制研究
经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。

173 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-02-12 LCXXXX 来自黑龙江省

投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？

141 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2021-12-31 1defd82cm50(暂无匿称)

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;生物信息
经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受

184 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-10-29 ms9000001657033209

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：药理
经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业

162 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211108, encodeId=20d12211108ad, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：2023年度影响因子2.3分，但是期刊前阵子被踢出，仍然风险很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:57:30 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2120894, encodeId=29af2120894d4, content=这个杂志被踢出sci了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Tue Mar 21 21:33:07 CST 2023, time=2023-03-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120913, encodeId=8e0e21209139c, content=小修修回，结果这本期刊被踢出sci了，怎么办，撤稿么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0278145464, createdName=ms6000002114457146, createdTime=Tue Mar 21 22:55:53 CST 2023, time=2023-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121991, encodeId=cfb2212199155, content=这个杂志在wos还能检索到吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sun Mar 26 23:55:12 CST 2023, time=2023-03-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121232, encodeId=19c42121232bb, content=偏重的研究方向：神经科学;免疫 经验分享：已被踢sci了，感觉撤稿重投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=Drwurh, createdTime=Wed Mar 22 23:41:31 CST 2023, time=2023-03-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2102140, encodeId=dd0e2102140fc, content=偏重的研究方向：生物信息学;药效学及机制研究 经验分享： 9-9 Submit 9-22 Under review 9-29 Pending approval 10-5 Submit revision 11-11 Under review (个人原因，修改稿上传的晚一些） 11-17 Pending approval 11-23 Accepted 投本杂志的第二篇。第一篇前后花了4个月的时间才录用。第二篇花了2月左右的时间，除了个人原因耽误了一段时间。总体来讲，第二篇比较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Nov 23 09:38:48 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114221, encodeId=7ad72114221b4, content=投了8天了，还在s u b m i t t e d，S E和A E都是u n a s s i g n e d状态，大家多久能进行到下一步？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLibA6fR6r7UBcywPX2ib4qynVzBf91GEBflgqjmYLicW2bt9t99TsSXf8iaLmYjXORutvzeRZd9LoPJQ/132, createdBy=2d692442768, createdName=LCXXXX, createdTime=Sun Feb 12 13:03:23 CST 2023, time=2023-02-12, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=1179256, encodeId=cae111e925699, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生物信息 经验分享：研究方向：肿瘤的生物信息学 2021-05-02投稿 2021-09-14收到审稿意见，大修 2021-10-13修回 2021-12-22接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e311736657, createdName=1defd82cm50(暂无匿称), createdTime=Fri Dec 31 13:09:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097346, encodeId=7d51209e346dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：药理 经验分享：大家pending approval大概多久，我已经半个月了，会不会被拒稿，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3f66513648, createdName=ms9000001657033209, createdTime=Sat Oct 29 20:08:54 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800786, encodeId=7c0a800e8695, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b091317808, createdName=mysteriousperfume, createdTime=Wed Jul 01 16:03:37 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2020-07-01 mysteriousperfume

审稿速度:2.0 | 投稿命中率:75.0
经验分享：连续被好几个三分多的杂志拒稿，有这个杂志，小修，二个月接受。

259 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务